Industry News

More Industry News

Image title

Aestus partners with nonprofit biotech institute to test ALS drugs
3/17/2010
Green alga holds promise for pharmaceutical production
3/17/2010
Roche plans to stay away from "mega-mergers," CEO says
3/17/2010

Aestus partners with nonprofit biotech institute to test ALS drugs

3/17/2010

The ALS Therapy Institute has agreed to collaborate with New Jersey-based Aestus Therapeutics to conduct studies on small-molecule drugs that could delay or halt the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease. The institute will be in charge of testing the compounds identified by Aestus using a preclinical model of the condition.

Regulatory News

Image title

FDA policy would accelerate approval of drug cocktails
3/18/2010
Ban on pay-for-delay deals might get dropped from health bill
3/17/2010
Drugmakers face scrutiny regarding domestic versus foreign prices
3/17/2010

FDA policy would accelerate approval of drug cocktails

3/18/2010

The FDA is formulating guidelines that would speed up testing and approval of multidrug cocktails for potentially life-threatening diseases that lack treatments. The policy is expected to benefit the Critical Path to TB Regimens, a collaboration of major drugmakers and nonprofit groups assembled by the Bill & Melinda Gates Foundation.

Online Newsletters

Kudos to companies extending themselves with superior manufacturing practices
02/10/2010
Boosting manufacturing efficiency: A look at new industry efforts
01/13/2010
Outsourcing API manufacturing – is the tide turning away from Asia?
12/09/2009
New CDC report, old lesson: Sterility in manufacturing is crucial
11/11/2009

As a Registered INTERPHEX365 Subscriber, you will be receiving monthly INTERPHEX365 Reporter newsletters electronically. This online publication, published in cooperation with SmartBrief, will summarize the highlights of each month with unique commentary on the industry news.

Issues of past monthly newsletters will be stored here in an Archive.

If you haven't already done so, we encourage you to Register to take full advantage of site functionality, including industry news and participation in the Business Discussion Forums.

Sign-up to receive the INTERPHEX365 Reporter